↓ Skip to main content

Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB

Overview of attention for article published in Journal of Immune Based Therapies and Vaccines, January 2011
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (69th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

facebook
1 Facebook page
wikipedia
2 Wikipedia pages

Citations

dimensions_citation
18 Dimensions

Readers on

mendeley
50 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB
Published in
Journal of Immune Based Therapies and Vaccines, January 2011
DOI 10.1186/1476-8518-9-3
Pubmed ID
Authors

Dmitry A Butov, Yuri N Pashkov, Anna L Stepanenko, Aleksandra I Choporova, Tanya S Butova, Dendev Batdelger, Vichai Jirathitikal, Aldar S Bourinbaiar, Svetlana I Zaitzeva

Abstract

Placebo-controlled, randomized, phase 2b trial was conducted in 34 adults comprising 18 first-diagnosed (52.9%), 6 relapsed (17.6%), and 10 MDR-TB (29.4%) cases to investigate the safety and efficacy of an oral immune adjunct (V5). The immunotherapy (N = 24) and placebo (N = 10) arms received once-daily tablet of V5 or placebo for one month in addition to conventional anti-TB therapy (ATT) administered under directly observed therapy (DOT).The enlarged liver, total bilirubin, erythrocyte sedimentation rate, lymphocyte and leukocyte counts improved significantly in V5 recipients (P = 0.002; 0.03; 8.3E-007; 2.8E-005; and 0.002) but remained statistically unchanged in the placebo group (P = 0.68; 0.96; 0.61; 0.91; and 0.43 respectively). The changes in hemoglobin and ALT levels in both treatment arms were not significant. The body weight increased in all V5-treated patients by an average 3.5 ± 1.8 kg (P = 2.3E-009), while 6 out of 10 patients on placebo gained mean 0.9 ± 0.9 kg (P = 0.01). Mycobacterial clearance in sputum smears was observed in 78.3% and 0% of patients on V5 and placebo (P = 0.009). The conversion rate in V5-receiving subjects with MDR-TB (87.5%) seemed to be higher than in first-diagnosed TB (61.5%) but the difference was not significant (P = 0.62). Scoring of sputum bacillary load (range 3-0) at baseline and post-treatment revealed score reduction in 23 out of 24 (95.8%) V5 recipients (from mean/median 2.2/3 to 0.3/0; P = 6E-010) but only in 1 out of 10 (10%) patients on placebo (1.9/1.5 vs. 1.8/1; P = 0.34). No adverse effects or TB reactivation were seen at any time during follow-up. V5 is safe as an immune adjunct to chemotherapeutic management of TB and can shorten substantially the duration of treatment.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 4%
Unknown 48 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 14 28%
Researcher 5 10%
Student > Postgraduate 4 8%
Student > Bachelor 4 8%
Student > Ph. D. Student 3 6%
Other 9 18%
Unknown 11 22%
Readers by discipline Count As %
Medicine and Dentistry 20 40%
Agricultural and Biological Sciences 6 12%
Pharmacology, Toxicology and Pharmaceutical Science 3 6%
Computer Science 2 4%
Immunology and Microbiology 2 4%
Other 6 12%
Unknown 11 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 November 2022.
All research outputs
#7,345,484
of 23,151,189 outputs
Outputs from Journal of Immune Based Therapies and Vaccines
#14
of 32 outputs
Outputs of similar age
#54,376
of 183,873 outputs
Outputs of similar age from Journal of Immune Based Therapies and Vaccines
#4
of 6 outputs
Altmetric has tracked 23,151,189 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 32 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.5. This one scored the same or higher as 18 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 183,873 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.